Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22268690 | 1.00 | EPHX1 (0.50) | EPHX1TRPA1SIGMAR1L3MBTL1PAOX | |
| SCHEMBL19226301 | 1.00 | EPHX1 (0.50) | EPHX1TRPA1SIGMAR1L3MBTL1PAOX | |
| SCHEMBL22268681 | 1.00 | EPHX1 (0.50) | EPHX1TRPA1SIGMAR1L3MBTL1PAOX | |
| SCHEMBL8374890 | 0.97 | — | — | |
| SCHEMBL1488093 | 0.88 | — | — | |
| SCHEMBL7519351 | 0.78 | EPHX1 (0.73) | EPHX1SIGMAR1L3MBTL1PAOXKDM4A | |
| SCHEMBL6838885 | 0.78 | EPHX1 (0.73) | EPHX1SIGMAR1L3MBTL1PAOXKDM4A | |
| SCHEMBL5909406 | 0.78 | EPHX1 (0.73) | EPHX1SIGMAR1L3MBTL1PAOXKDM4A | |
| SCHEMBL7519363 | 0.78 | EPHX1 (0.73) | EPHX1SIGMAR1L3MBTL1PAOXKDM4A | |
| SCHEMBL331550 | 0.78 | EPHX1 (0.73) | EPHX1SIGMAR1L3MBTL1PAOXKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| US-11090413-B2 | Modified alginates for anti-fibrotic materials and applications | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190184067-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090413-B2 | Modified alginates for anti-fibrotic materials and applications | ALG1, FIBP, COL2A1 | EPHX1 3857/4885TRPA1 2038/4885SIGMAR1 1486/4885 |
| US-20190184067-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | EPHX1 3857/4885TRPA1 2038/4885SIGMAR1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.